These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 31412614)

  • 1. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
    Gatto F; Barbieri F; Arvigo M; Thellung S; Amarù J; Albertelli M; Ferone D; Florio T
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
    Gatto F; Arvigo M; Ferone D
    J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
    Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
    Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
    Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
    Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Somatostatin Receptor Subtype-3 (SST
    Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
    Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
    Schaer JC; Waser B; Mengod G; Reubi JC
    Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
    Reubi JC; Schonbrunn A
    Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
    Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
    Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
    Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
    Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin-dopamine ligands in the treatment of pituitary adenomas.
    Saveanu A; Jaquet P
    Rev Endocr Metab Disord; 2009 Jun; 10(2):83-90. PubMed ID: 18651224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
    Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
    Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.